Because the drug is so effective, we might be able to reduce the dosage and thus alleviate some of the side results in the future– though we still dont know how people respond to the drug,” he says.Testing of the brand-new weight loss drug is still in the so-called preclinical phase, which is based on research studies with cells and on experimental animals. What is interesting here is the effect we get when we combine these two compounds into a single drug,” Christoffer Clemmensen stresses.The drug must go through three stages of medical trials on human participants. Without GLP-1, the particles that target the NMDA receptor would affect the entire brain and therefore be non-specific,” says Postdoc Jonas Petersen from the Clemmensen Group, who is the first author on the chemist and the research study who synthesized the molecules.Non-specific drugs are often associated with severe side impacts, which have previously been seen in drugs for dealing with various neurobiological conditions.
“I consider the drugs readily available on the significant today as the very first generation of weight-loss drugs. The new drug might be an alternative to those who do not respond well to existing weight-loss drugs. Because the drug is so reliable, we may be able to decrease the dose and thus reduce some of the side effects in the future– though we still do not understand how people respond to the drug,” he says.Testing of the new weight loss drug is still in the so-called preclinical phase, which is based on studies with cells and on experimental animals. What is intriguing here is the impact we get when we combine these 2 substances into a single drug,” Christoffer Clemmensen stresses.The drug must undergo 3 phases of medical trials on human individuals. Without GLP-1, the particles that target the NMDA receptor would affect the whole brain and hence be non-specific,” says Postdoc Jonas Petersen from the Clemmensen Group, who is the very first author on the chemist and the study who manufactured the molecules.Non-specific drugs are frequently associated with extreme side impacts, which have formerly been seen in drugs for treating various neurobiological conditions.
